EpiStem Holdings plc
23 October 2007
EXECUTIVE DIRECTOR AWARDED SHARE OPTIONS
Manchester, UK, 23rd October 2007 - Epistem Holdings Plc (AIM: EHP) announced
today that Dr Gerard Brady, Research Director, has been awarded share options as
detailed below. The share options will vest according to the performance and
delivery of the Company's robotic Biomarker technology platform. For the share
options to fully vest at the end of the three year period would require
Epistem's Biomarker technology to be established by the third year of grant.
The share options have an exercise price of 160 pence, being the closing share
price on 15th October 2007.
Following this award, Dr Brady will hold the following numbers of share options:
Executive Share option New share options Total share option Share options held as
Director holding prior to granted holding after % of issued capital
award award
Dr Gerard Brady 132,877 57,725 190,602 2.92%
In July 2007, just following the Company's admission to AIM, Dr Gerard Brady
also received 12,653 options under the Enterprise Management Incentive (EMI)
scheme at an exercise price of 167p for his performance and contribution in
progressing the Company's Novel Therapeutic development program.
For further information, please contact:
Matthew Walls
CEO
Epistem Holdings Plc 0161 606 7258
Thilo Hoffmann
Landsbanki Securities UK 0207 426 9000
Mike Wort, Anna Dunphy
MC Bio-Communications 0207 744 7711
- ENDS -
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.